Provexis reduces losses

Sports nutrition company Provexis said it narrowed losses during the first half of its financial year and believes it is poised to make further progress.

Sports nutrition company Provexis said it narrowed losses during the first half of its financial year and believes it is poised to make further progress.

Underlying operating losses narrowed to £0.51m for the six months ended September 30th 2012 compared to a loss of £1.03m a year earlier. Revenues for the period increased to £3.26m from £1.53m previously.

Provexis, which develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, said cash balance at the end of September was £1.4m compared to £2.8m in 2011.

Stephen Moon, Chief Executive Officer commented: "We are very pleased with the progress made with our Science in Sport business, which has continued to grow despite some very tough trading conditions across the sector, including the effect of the extremely poor weather in June and July."

"With broadened distribution, margin improvements feeding into increased marketing and sales investment, and a healthy innovation pipeline, we are confident of continued progress in the second half," he added.

Meanwhile Fruitflow continues to make progress, with nine regional consumer products now on the market around the globe and more to follow in the second half of the year, the group explained.

"With a commercially viable tablet grade format now complete, we have reached a major milestone, as this gives us access to the dietary supplement sector. We continue to work very closely with DSM on developing further consumer understanding of Fruitflow and in regulatory matters," Moon said.

Provexis said it is now seeing significantly reduced operating losses after its restructuring programme and it continues to seek further cost savings and efficiency improvements.

"The economic climate remains very challenging, but with our continued commitment to focusing on the twin revenue streams of SiS and Fruitflow, while managing costs carefully, we believe the business is well placed to make further progress."

CJ

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
23 Jan 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023
Investing trends to watch out for in 2023: what analysts say
Investment strategy

Investing trends to watch out for in 2023: what analysts say

What are sensible strategies for high inflationary times? We ask analysts to find out.
22 Dec 2022

Most Popular

When will interest rates go up?
UK Economy

When will interest rates go up?

Interest rates are now at 4%, and they could rise further in the months ahead.
3 Feb 2023
NS&I brings back one-year fixed bonds with highest rates since 2010
Personal finance

NS&I brings back one-year fixed bonds with highest rates since 2010

NS&I’s one-year fixed bonds are back on sale after being pulled off the market in 2019 - but is the rate any good?
1 Feb 2023
Covid-19 vaccines helped these stocks take off, but what’s next for these companies?
Investments

Covid-19 vaccines helped these stocks take off, but what’s next for these companies?

Dominic Frisby explores how the top vaccine stocks are doing as booster take-up remains at a low
2 Feb 2023